Primary Immunodeficiency Disease Clinical Trial
Official title:
Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment in Patients Who Did Not Tolerate Other 20% Subcutaneous Immunoglobulin Product(s)
Patients with primary or secondary immunodeficiency disease who have developed adverse reactions to products available on the market such as Cuvitru® (Shire), Hizentra® (CSL Behring) or 10% Gammunex® (Grifols), may benefit from utilizing 16.5% Cutaquig® (Octapharma).
This is a prospective interventional study before and after clinically driven change in
treatment formulation.
Polyvalent immunoglobulin treatment is used in patients with primary or secondary antibody
deficiency diseases to prevent and lower the risk of infection. There are multiple products
available in the market. Most products are administered via intravenous route such as
Privigen® (CSL Behring), Gammunex® (Grifols), and Panzyga® (Octapharma). Up until recently,
there have been only two products that are licensed for subcutaneous administration - 20%
Hizentra® (CSL Behring) and 10% Gammunex® (Grifols).
In our clinical experience, approximately 10% of patients treated with 20% Hizentra®
developed adverse reactions. Some are mild and tolerable. Some are moderate to severe and
required alteration of treatment plan: For example, changing the product from 20% Hizentra®
to 10% Gammunex®. However, this results in a 100% increase in the injection volume due to the
lesser concentration of the product, but a decrease in viscosity - both of which might alter
overall tolerance. Likewise, any new treatment may bring new adverse events such as rash.
In 2018, there will be two additional subcutaneous immunoglobulin products available in
Canada - 16.5% Cutaquig® (Octapharma) and 20% Cuvitru® (Shire).
Even though both new products are licensed and proven to be efficacious regarding preventing
significant infection (1,2), the relative safety, tolerability, patient satisfaction,
treatment-associated cost has not been studied in patients using the 16.5% Cutaquig®. The
study product will be provided through the Canadian Blood Service (CBS) on a special request
basis which is a standard procedure for any patients who are intolerable to inventory
products.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02810444 -
Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
|
Phase 3 | |
| Enrolling by invitation |
NCT01150240 -
Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland
|
N/A | |
| Recruiting |
NCT04944979 -
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
|
Phase 3 | |
| Completed |
NCT02627300 -
Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial
|
Phase 3 | |
| Not yet recruiting |
NCT03252548 -
Pediatric Primary Immunodeficiency Disease (PID) in China
|
N/A | |
| Completed |
NCT03961009 -
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients
|
Phase 3 | |
| Active, not recruiting |
NCT04842643 -
An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease
|
Phase 3 | |
| Not yet recruiting |
NCT06089122 -
Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG
|
Phase 3 | |
| Not yet recruiting |
NCT06150833 -
Efficacy and Safety and Pharmacokinetics of Boya IVIG
|
Phase 3 |